Rallybio Corporation RLYB
Set alert
As of Nov 3, 12:48 PM ET
- YTD
- +189.25%
- 1 year
- +197.38%
- Open
- 15.76
- Prev close
- 15.76
- Mkt cap
- 85.50M
- Vol
- 11.96K
- Avg vol
- 16.90K
- EPS
- 4.61
- P/E
- 3.44
- Div yield
- 0.00%
More statistics
- Low
- 15.72
- High
- 16.11
- Forward P/E
- -0.72
- Beta
- -1.67
- Short ratio
- 5.26
- Inst. own
- 76.27%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.05
- 200-d avg
- 1.35
- 1y target
- 8.25
5D chart
Signals (85)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 3:55 PM | 21 hours ago |
| MACD: Sell Signal | Nov 2, 3:55 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 3:40 PM | 21 hours ago |
| SMA: Bearish | Nov 2, 3:35 PM | 21 hours ago |
| MACD: Buy Signal | Nov 2, 3:25 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 3:05 PM | 21 hours ago |
| SMA: Bearish | Nov 2, 2:00 PM | 23 hours ago |
| SMA: Bearish | Nov 2, 2:00 PM | 23 hours ago |
| SMA: Bullish | Nov 2, 1:55 PM | 23 hours ago |
| SMA: Bullish | Nov 2, 1:55 PM | 23 hours ago |
| SMA: Bearish | Nov 2, 1:50 PM | 23 hours ago |
| SMA: Bearish | Nov 2, 1:50 PM | 23 hours ago |
| SMA: Bullish | Nov 2, 1:45 PM | 23 hours ago |
| SMA: Bullish | Nov 2, 1:45 PM | 23 hours ago |
| SMA: Bearish | Nov 2, 1:40 PM | 23 hours ago |
| SMA: Bearish | Nov 2, 1:40 PM | 23 hours ago |
| SMA: Bullish | Nov 2, 12:55 PM | 1 day ago |
| SMA: Bullish | Nov 2, 12:55 PM | 1 day ago |
| SMA: Bearish | Nov 2, 12:50 PM | 1 day ago |
| SMA: Bearish | Nov 2, 12:50 PM | 1 day ago |
Newest 20 of 85.
News
-
1 week ago benzinga.com
Rallybio Q3 EPS $(0.48) Misses $(0.21) Estimate
Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.21) by 128.57 percent. This is a 57.14 percent increase over losses of $(1.12)…
-
1 week ago benzinga.com
Rallybio Declares $82.7M Special Cash Distribution To Stockholders And Pre-Funded Warrant Holders, Estimated At $13.56/Share, In Connection With Avenzo Therapeutics Merger
As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement")…
1 week ago businesswire.com
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Rallybio…
1 month ago defenseworld.net
Rallybio (NASDAQ:RLYB) Stock Price Up 1.9% – Should You Buy?
Shares of Rallybio Corporation (NASDAQ: RLYB - Get Free Report) traded up 1.9% during trading on Friday. The stock traded as high as $17.22 and last traded at $17.08. Approximately 7,854 shares…
3 months ago gurufocus.com
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 21, 2026
3 months ago prnewswire.com
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
4 months ago gurufocus.com
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 9, 2026
4 months ago prnewswire.com
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
5 months ago gurufocus.com
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick and Foti, LLC (âKSFâ) are investigating the proposed merger of
5 months ago businesswire.com
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Rallybio…
5 months ago prnewswire.com
Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders
MILWAUKEE, June 2, 2026 /PRNewswire/ -- Ademi LLP is investigating Rallybio (Nasdaq: RLY) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction…
5 months ago seekingalpha.com
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
5 months ago gurufocus.com
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics, Inc. Upon closing of
5 months ago businesswire.com
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics, Inc. Upon closing of the proposed…
-
5 months ago benzinga.com
Rallybio To Acquire Avenzo Therapeutics; Avenzo Entered Into $215M Private Placement Financing
About the Proposed Transaction Under the terms of the merger agreement, Rallybio will acquire Avenzo pursuant to the Merger. At the closing of the Merger, Avenzo stockholders will receive newly…
5 months ago businesswire.com
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
NEW HAVEN, Conn. & SAN DIEGO, Calif.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing…
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
6 months ago benzinga.com
Why eBay Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
eBay (NASDAQ: EBAY) rose sharply after GameStop (NYSE: GME) proposed to acquire it for $125/share, valuing GME at $55.5B. eBay shares jumped 8.1% to $112.50 in pre-market trading.
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
6 months ago prnewswire.com
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
7 months ago prnewswire.com
Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
7 months ago globenewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—EWCZ, STEL, RLYB, and CTRA
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders…
7 months ago globenewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—ALIS, TALK, JTAI, and RLYB
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders…
8 months ago prnewswire.com
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
8 months ago businesswire.com
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Rallybio…
8 months ago seekingalpha.com
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
8 months ago benzinga.com
Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism
Rallybio stock jumps after announcing a $505 million merger with Candid Therapeutics, boosting cash to $700 million.
-
8 months ago benzinga.com
Rallybio To Acquire Candid Therapeutics Under All-Stock Merger Agreement
Following closing, pre-Transaction Rallybio equityholders are expected to own approximately 3.65% of the combined company, and pre-Transaction Candid equityholders (inclusive of investors…
8 months ago benzinga.com
Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026
Rallybio reports strong Phase 1 results for RLYB116, showing full immune pathway control with good safety and Phase 2 plans ahead.
-
8 months ago benzinga.com
Rallybio Reports Results From Phase 1 Confirmatory PK/PD Clinical Trial Evaluating RLYB116 In Development For Patients With Complement-Mediated Diseases With Initial Focus On Immune PTR And Refractory APS
– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases –– Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion…
-
9 months ago benzinga.com
Rallybio Announces 1-For-8 Reverse Stock Split
Rallybio Corporation (NASDAQ:RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio's Amended and…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
12 months ago benzinga.com
UPDATE: Rallybio Q3 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $212.000K Beat $66.667K Estimate
Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.21) by 34.58 percent. This is a 46.15 percent increase over losses of $(0.26)…
-
12 months ago benzinga.com
Rallybio Q3 EPS $0.36 Beats $(0.21) Estimate, Sales $212.000K Beat $66.667K Estimate
Rallybio (NASDAQ:RLYB) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $(0.21) by 269.01 percent. This is a 238.46 percent increase over losses of $(0.26)…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
Rallybio Completes Dosing For First Cohort In Phase 1 Confirmatory PK/PD Study Of RLYB116 Its Once-Weekly, Small-Volume, Subcutaneous C5 Inhibitor Being Developed To Treat Rare Diseases
Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
Rallybio Q2 EPS $(0.22) Beats $(0.24) Estimate, Sales $212.000K Down From $299.000K YoY
Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 10.2 percent. This is a 40.54 percent increase over losses of $(0.37) per…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
1 year ago benzinga.com
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments.
-
1 year ago benzinga.com
Recursion Acquires Rallybio's Full Interest In Joint ENPP1 Inhibitor Program And Associated Backup Molecule For Treatment Of Hypophosphatasia; Rallybio To Receive $7.5M Upfront, With Potential For $17.5M More In Preclinical And Clinical Milestones
Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
Rallybio Initiates Dosing In Phase 1 Confirmatory PK/PD Study Evaluating RLYB116, Subcutaneously Injected C5 Inhibitor
– Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refractoriness and Refractory Antiphospholipid Syndrome –– Data Readouts…